Cited by 5,228Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver physiology and pathology

The DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index, and 2 are not checked yet.

Nonalcoholic Fatty Liver Disease

Angulo, Paul·2002·New England Journal of Medicine

DOI 10.1056/nejmra011775

Open this paper in CoChat — free account

Abstract

Alcohol abuse is the most common cause of fatty liver disease, but it is now apparent that fat deposition in the liver, and its consequences, may occur without alcohol abuse. The principal risk factors are obesity, non-insulin-dependent diabetes mellitus, and hyperlipidemia. The disorder has a wide clinical spectrum, ranging from asymptomatic steatosis to steatohepatitis, fibrosis, and cirrhosis. This article provides a broad overview of this increasingly recognized liver disease.

Integrity signals

Registry

Crossref · 10.1056/nejmra011775

Cites

90 of 92 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon‐Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,973
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078

Show all 90 references

Research works printed but not linked: 9

Schaffner F, 1986, Prog Liver Dis, 8, 283
Itoh S, 1987, Am J Gastroenterol, 82, 650
Silverman JF, 1990, Am J Gastroenterol, 85, 1349
Creutzfeldt W, 1970, Prog Liver Dis, 3, 371
Silverman JF, 1989, Pathol Annu, 24, 275
Debaere C, 1998, J Belge Radiol, 81, 174
Zatloukal K, 1991, Lab Invest, 64, 200
Curzio M, 1985, Int J Tissue React, 7, 137
Watson AM, 1999, Drug Metab Dispos, 27, 695

Sorted by citations

Items 201–300 of 1,031

Nonalcoholic fatty liver disease: A review of current understanding and future impact
Charlton, M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00440-9 · Cited by 351
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 350
Treatment of non-alcoholic fatty liver disease
Adams, L. A., & Angulo, P. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042200 · Cited by 350
Self-citation
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography
Myers, R. P., Pollett, A. F., Kirsch, R., Pomier–Layrargues, G., Beaton, M. D., Levstik, M. A., Duarte‐Rojo, A., Wong, D., Crotty, P., & Elkashab, M. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02781.x · Cited by 350
Nonalcoholic Fatty Liver Disease: US-based Acoustic Radiation Force Impulse Elastography
Yoneda, M., Suzuki, K., Kato, S., Fujita, K., Nozaki, Y., Hosono, K., Saito, S., & Nakajima, A. (2010) · Radiology · doi:10.1148/radiol.10091662 · Cited by 349
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease
Palmeri, M. L., Wang, M. H., Rouze, N. C., Abdelmalek, M. F., Guy, C. D., Moser, B. K., Diehl, A. M., & Nightingale, K. R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.019 · Cited by 348
Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis
Yokoo, T., Serai, S. D., Pirasteh, A., Bashir, M. R., Hamilton, G., Hernando, D., Hu, P., Hetterich, H., Kühn, J., Kukuk, G. M., et al. (2017) · Radiology · doi:10.1148/radiol.2017170550 · Cited by 346
Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease
Parekh, S., & Anania, F. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.055 · Cited by 344
Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
Kim, C. H., & Younossi, Z. M. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.721 · Cited by 343
Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341
Assessment of Hepatic Steatosis in Patients Undergoing Liver Resection: Comparison of US, CT, T1-weighted Dual-Echo MR Imaging, and Point-resolved1H MR Spectroscopy
van Werven, J. R., Marsman, H. A., Nederveen, A. J., Smits, N. J., ten Kate, F. J. W., van Gulik, T. M., & Stoker, J. (2010) · Radiology · doi:10.1148/radiol.10091790 · Cited by 341
Increased expression of PPARγ in high fat diet-induced liver steatosis in mice
Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., Suzuki, Y., Saito, H., Kohgo, Y., & Okumura, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.070 · Cited by 340
Soft Drink Consumption Linked with Fatty Liver in the Absence of Traditional Risk Factors
Assy, N., Nasser, G., Kamayse, I., Nseir, W., Beniashvili, Z., Djibre, A., & Grosovski, M. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/810961 · Cited by 340
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih, M., & Jornayvaz, F. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.018 · Cited by 336
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Smith, B. W., & Adams, L. A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.72 · Cited by 334
Adipocyte Signaling and Lipid Homeostasis
Yu, Y., & Ginsberg, H. N. (2005) · Circulation Research · doi:10.1161/01.res.0000165803.47776.38 · Cited by 334
Noninvasive proteomic biomarkers for alcohol-related liver disease
Niu, L., Thiele, M. S., Geyer, P. E., Rasmussen, D. N., Webel, H. E., Santos, A., Gupta, R., Meier, F., Strauss, M. T., Kjærgaard, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01850-y · Cited by 332
Diacylglycerol Activation of Protein Kinase Cε and Hepatic Insulin Resistance
Jornayvaz, F. R., & Shulman, G. I. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.005 · Cited by 331
Small Intestinal Bacterial Overgrowth: Roles of Antibiotics, Prebiotics, and Probiotics
Quigley, E. M. M., & Quera, R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.046 · Cited by 330
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez‐López, S., Francés, R., & Gómez‐Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 330
Clinical Biochemistry of Hepatotoxicity
Sharma, O. P. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.s4-001 · Cited by 329
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Mueller, M., Thorell, A., Claudel, T., Jha, P., Köfeler, H. C., Lackner, C., Hoesel, B., Fauler, G., Stojaković, T., Einarsson, C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.034 · Cited by 327
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease†
Merriman, R. B., Ferrell, L. D., Patti, M. G., Weston, S. R., Pabst, M. S., Aouizerat, B. E., & Bass, N. M. (2006) · Hepatology · doi:10.1002/hep.21346 · Cited by 325
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, J. W., Konopski, Z., Eggesbø, H. B., von Volkmann, H. L., Raschpichler, G., Bjøro, K., Haaland, T., Løberg, E. M., & Birkeland, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902845268 · Cited by 323
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
Bellentani, S., & Marino, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31820-4 · Cited by 322
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis
Kral, J. G., Thung, S. N., Biron, S., Hould, F.-S., Lebel, S., Marceau, S., Simard, S., & Marceau, P. (2004) · Surgery · doi:10.1016/j.surg.2003.10.003 · Cited by 322
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
Feldstein, A. E., Canbay, A. E., Guicciardi, M. E., Higuchi, H., Bronk, S. F., & Gores, G. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00460-4 · Cited by 321
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
Suzuki, A., Lindor, K. D., Sauver, J. S., Lymp, J. F., Mendes, F. D., Muto, A., Okada, T., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.008 · Cited by 320
Self-citation
Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Nonalcoholic fatty liver disease is associated with coronary artery calcification
Kim, D., Choi, S., Park, E. H., Lee, W., Kang, J. H., Kim, W. K., Kim, Y. J., Yoon, J., Jeong, S., Lee, D. H., et al. (2012) · Hepatology · doi:10.1002/hep.25593 · Cited by 318
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.004 · Cited by 317
Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke
Weikert, C., Stefan, N., Schulze, M. B., Pischon, T., Berger, K., Joost, H., Häring, H., Boeing, H., & Fritsche, A. (2008) · Circulation · doi:10.1161/circulationaha.108.814418 · Cited by 315
Metformin
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
The role of oxidative stress in non-alcoholic steatohepatitis
Koek, G. H., Liedorp, P. R., & Bast, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.013 · Cited by 315
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 315
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice
Oben, J. A., Mouralidarane, A., Samuelsson, A.-M., Matthews, P. J., Morgan, M. L., Mckee, C., Soeda, J., Fernandez-Twinn, D. S., Martin-Gronert, M. S., Ozanne, S. E., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.042 · Cited by 314
Non‐alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines
Chitturi, S., Farrell, G. C., Hashimoto, E., Saibara, T., Lau, G. K. K., Sollano, J. D., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05001.x · Cited by 312
Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Wang, H. H., Lee, D. K., Liu, M., Portincasa, P., & Wang, D. Q. ‐. (2020) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2020.23.3.189 · Cited by 309
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 309
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
Festi, D., Colecchia, A., Sacco, T., Bondi, M., Roda, E., & Marchesini, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00126.x · Cited by 308
Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease
Yoneda, M., Naka, S., Nakano, K., Wada, K., Endo, H., Mawatari, H., Imajo, K., Nomura, R., Hokamura, K., Ono, M., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-16 · Cited by 307
Gender and racial differences in nonalcoholic fatty liver disease
Pan, J. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.274 · Cited by 307
Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review
Chaston, T. B., & Dixon, J. B. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803761 · Cited by 307
Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence
Zelber‐Sagi, S. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i29.3377 · Cited by 307
Genetic Basis for Sex Differences in Obesity and Lipid Metabolism
Link, J. C., & Reue, K. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064827 · Cited by 306
Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene
Kantartzis, K., Peter, A., Machicao, F. E., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 305
Mildly elevated liver transaminase levels in the asymptomatic patient.
Giboney, P. (2005) · PubMed · Cited by 303
Fatty liver and lipotoxicity
Trauner, M., Arrese, M. A., & Wagner, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.007 · Cited by 302
The pan‐caspase inhibitor Emricasan ( IDN ‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2014) · Liver International · doi:10.1111/liv.12570 · Cited by 302
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
the LIDO Study Group and the CYTOL study group, Poynard, T., Ratziu, V., Charlotte, F., Messous, D., Munteanu, M., Imbert‐Bismut, F., Massard, J., Bonyhay, L., Tahiri, M., et al. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-34 · Cited by 302
Histopathology of hepatocellular carcinoma
Schlageter, M., Terracciano, L., D’Angelo, S., & Sorrentino, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.15955 · Cited by 301
Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive
Wieckowska, A., & Feldstein, A. E. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091983 · Cited by 301
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Feldstein, A. E., López, R., Tamimi, T., Yerian, L. M., Chung, Y.-M., Berk, M. P., Zhang, R., McIntyre, T. M., & Hazen, S. L. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m007096 · Cited by 301
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 300
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
Preiss, D., & Sattar, N. A. (2008) · Clinical Science · doi:10.1042/cs20070402 · Cited by 297
Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., & Oren, R. (2008) · Hepatology · doi:10.1002/hep.22525 · Cited by 296
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
Spadaro, L., Magliocco, O., Spampinato, D., Piro, S., Oliveri, C. E., Alagona, C., Papa, G. F. S., Rabuazzo, A. M., & Purrello, F. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.003 · Cited by 296
The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicity
Li, Z.-Z., Berk, M. P., McIntyre, T. M., Gores, G. J., & Feldstein, A. E. (2008) · Hepatology · doi:10.1002/hep.22183 · Cited by 296
Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3
Lee, J. H., Budanov, A. V., Talukdar, S., Park, E. J., Park, H. L., Park, H.-W., Bandyopadhyay, G., Li, N., Aghajan, M., Jang, I., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.004 · Cited by 295
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S. R., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 293
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice
Ritze, Y., Bárdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., & Bischoff, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080169 · Cited by 292
Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated With Nonalcoholic Fatty Liver Disease
Klein, S., Mittendorfer, B., Eagon, J. C., Patterson, B. W., Grant, L. M., Feirt, N. M., Seki, E., Brenner, D. A., Korenblat, K., & McCrea, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.042 · Cited by 292
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition
Cave, M. C., Deaciuc, I. V., Mendez, C. M., Song, Z., Joshi‐Barve, S., Barve, S. S., & McClain, C. J. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.12.006 · Cited by 292
Diagnostic Value of a Computerized Hepatorenal Index for Sonographic Quantification of Liver Steatosis
Webb, M., Yeshua, H., Zelber‐Sagi, S., Santo, E., Brazowski, E., Halpern, Z., & Oren, R. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.07.4016 · Cited by 292
Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 291
Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures
Zelber‐Sagi, S., Nitzan, D., Halpern, Z., & Oren, R. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01311.x · Cited by 291
Nonalcoholic Fatty Liver Disease
Adams, L. A., & Lindor, K. D. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.05.013 · Cited by 291
Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin
Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes
Choi, Y.-J., Shin, H.-S., Choi, H. S., Park, J.-W., Jo, I., Oh, E., Lee, K.-Y., Lee, B., Johnson, R. J., & Kang, D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.98 · Cited by 290
Liver X receptor in cooperation with SREBP‐1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease
Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yamashita, N., Kohjima, M., Kotoh, K., Nakamuta, M., Takayanagi, R., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00382.x · Cited by 290
The metabolic consequences of childhood obesity
Weiss, R., & Caprio, S. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.04.009 · Cited by 288
Molecular mechanisms involved in NAFLD progression
Malaguarnera, M., Rosa, M. D., Nicoletti, F., & Malaguarnera, L. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0464-1 · Cited by 288
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
n−3 Fatty acids and the metabolic syndrome
Carpentier, Y., Portois, L., & Malaisse, W. J. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1499s · Cited by 286
Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
Angelico, F., Ben, M. D., Conti, R., Francioso, S., Feole, K., Fiorello, S., Cavallo, M. G., Zalunardo, B., Lirussi, F., Alessandri, C., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1024 · Cited by 286
Steatosis as a Risk Factor in Liver Surgery
inen, R. V., van Vliet, A. K., Gouma, D. J., & van Gulik, T. M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000225113.88433.cf · Cited by 285
Noninvasive evaluation of NAFLD
Castéra, L., Vilgrain, V., & Angulo, P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.175 · Cited by 283
Self-citation
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
Zelber‐Sagi, S., Lotan, R., Shlomai, A., Webb, M., Harrari, G., Buch, A., Nitzan, D., Halpern, Z., & Oren, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.011 · Cited by 283
Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes
Yang, Z., Miyahara, H., & Hatanaka, A. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-120 · Cited by 283
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280
Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease
Povero, D., Eguchi, A., Li, H., Johnson, C. D., Papouchado, B. G., Wree, A., Messer, K. S., & Feldstein, A. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113651 · Cited by 280
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. (2014) · Hepatology · doi:10.1002/hep.26695 · Cited by 279
Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD)
Yoneda, M., Fujita, K., Inamori, M., Nakajima, A., Tamano, M., & Hiraishi, H. (2007) · Gut · doi:10.1136/gut.2007.126417 · Cited by 279
A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism
Xu, Y., Zalzala, M. H., Xu, J., Li, Y., Yin, L., & Zhang, Y. (2015) · Nature Communications · doi:10.1038/ncomms8466 · Cited by 279
Obesity-induced Insulin Resistance and Hyperglycemia
Martyn, J. A. J., Kaneki, M., Yasuhara, S., Warner, D. S., & Warner, M. A. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181799d45 · Cited by 278
Alanine Aminotransferase-Old Biomarker and New Concept: A Review
Liu, Z., Que, S., Xu, J., & Peng, T. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8951 · Cited by 278
Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection
de Meijer, V. E., Kalish, B. T., Puder, M., & IJzermans, J. N. M. (2010) · British journal of surgery · doi:10.1002/bjs.7194 · Cited by 277
Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase
SHANG, J., CHEN, L.-L., XIAO, F.-X., SUN, H., DING, H.-C., & XIAO, H. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00807.x · Cited by 274
Metabolism of Alcohol
Lieber, C. S. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.10.005 · Cited by 274
Fatty liver in non‐alcoholic non‐overweight Japanese adults: Incidence and clinical characteristics
Omagari, K., Kadokawa, Y., Masuda, J., Egawa, I., Sawa, T., Hazama, H., Ohba, K., Isomoto, H., Mizuta, Y., Hayashida, K., et al. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02846.x · Cited by 274
Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria
Rapp, K., Schroeder, J. C., Klenk, J., Ulmer, H., Concin, H., Diem, G., Oberaigner, W., & Weiland, S. K. (2006) · Diabetologia · doi:10.1007/s00125-006-0207-6 · Cited by 274
High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease
Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut · doi:10.1136/gut.2008.151977 · Cited by 273
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.013 · Cited by 272
Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental‐Mendía, L. E., & Sahebkar, A. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000406 · Cited by 272
What are the risk factors and settings for non‐alcoholic fatty liver disease in Asia–Pacific?
Fan, J., Saibara, T., Chitturi, S., Kim, B. I., Sung, J. J. �., Chutaputti, A., & NAFLD, T. A. W. P. F. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04952.x · Cited by 270
Dietary habits and nutrient intake in non-alcoholic steatohepatitis
Toshimitsu, K., Matsuura, B., Ohkubo, I., Niiya, T., Furukawa, S., Hiasa, Y., Kawamura, M., Ebihara, K., & Onji, M. (2006) · Nutrition · doi:10.1016/j.nut.2006.09.004 · Cited by 269

Authors: Angulo, P.
Affiliations: Mayo Clinic (US)
Corresponding author: Angulo, Paul
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2002-04-18
Volume: 346
Issue: 16
Pages: 1221-1231
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra011775
OpenAlex: W2040109162
Cited by: 5,228
References: 90
Citations by year: 2026: 38 · 2025: 80 · 2024: 102 · 2023: 171 · 2022: 155 · 2021: 191 · 2020: 246 · 2019: 228 · 2018: 222 · 2017: 264 · 2016: 275 · 2015: 339 · 2014: 368 · 2013: 319 · 2012: 309
FWCI: 23.15
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: non-alcoholic fatty liver disease, hepatic steatosis, steatohepatitis, liver fibrosis, liver cirrhosis, obesity, type 2 diabetes, hyperlipidemia, risk factors, alcohol abuse
MeSH terms: Biopsy, Fatty Liver, Humans, Liver, Liver Function Tests, Radiography, Risk Factors, Ultrasonography, Weight Loss, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonalcoholic Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks